PLX Protalix BioTherapeutics, Inc. Total Debt to Capital

Protalix BioTherapeutics (PLX) relies on its unique ProCellEx plant-based protein synthesis system, establishing a protected scientific foundation for B2B collaboration while adhering to ESG principles by minimizing harmful emissions and resource consumption. Historical price action on the GURU.Markets platform shows that the total debt-to-equity ratio stands at 0.13, while the technology stack is undergoing a smooth modernization phase as part of its niche development.

Protalix BioTherapeutics, under the leadership of Dror Bashan, is developing the innovative ProCellEx platform for the treatment of orphan diseases. The total liabilities-to-equity ratio quantifies the financial stability of such capital-intensive developments. This coefficient measures the extent of the business's dependence on external borrowings relative to its net worth. High leverage increases risks during periods of rising interest rates. By analyzing the dynamics of the debt-to-equity ratio, an investor assesses the balance between growth and solvency.